ANAB AnaptysBio, Inc. - Fundamental Analysis
BULLISH
Sign in to save
Save this symbol to a watchlist or track a position.
ANAB Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$64.81
Analyst Target
$75.33
+16.2%
Upside
52W High
$66.66
52W Low
$15.32
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
87%
Analysis Accuracy
ANAB's Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 2/9, indicating significant distress risk, and no Altman Z-Score available, which raises red flags for solvency. Despite this, the company exhibits extraordinary growth momentum with 151% YoY revenue growth and a stellar 319.4% YoY EPS growth, supported by consistent earnings beat rates and large positive surprises. The stock trades at a premium valuation (Price/Sales: 7.94, Price/Book: 48.80), but this is justified by its high-growth biotech profile and strong analyst consensus. Insider selling activity is bearish, but the magnitude of recent earnings upside and market momentum suggest underlying strength. The overall picture reflects a high-risk, high-reward speculative opportunity.
Key Strengths
Exceptional 151.10% YoY revenue growth and 319.4% YoY EPS growth
Strong earnings beat rate (3/4 in last 4 quarters) with average surprise of 75.37%
High operating margin (61.80%) despite negative net profit margin
Analyst consensus of 'strong_buy' with a target price of $75.33 (17.5% upside)
Significant 1-year price appreciation (+284.9%) and strong momentum (17.3% in 1 month)
Key Risks
Piotroski F-Score of 2/9 indicates severe financial distress and weak operational health
Debt/Equity ratio of 7.81 is extremely high, signaling financial leverage risk
Negative ROE (-24.49%) and negative net profit margin (-5.64%) despite strong operating performance
Insider selling of $3.12M in last 6 months, including CEO and CFO, suggesting lack of confidence
No Graham Number or intrinsic value estimate, and no dividend, making valuation purely growth-based
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ANAB against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning ANAB from our newsroom.
Newest → oldest
No matching news yet.